October 23rd, 2013 by Jerusha Michael
CleveMed, a leading Home Sleep Testing (HST) manufacturer, announces the integration between its SleepView web-based technology and ProAct Health Solutions national HST program. The SleepView® Monitor is the market’s smallest and lightest, Type III portable home sleep monitor. It allows patients to be tested for Obstructive Sleep Apnea (OSA) in the comfort, convenience and privacy of their own home. The SleepView web portal provides prescribing physicians with secure, HIPAA compliant online access to sleep study reports generated by board certified sleep physicians and a pathway to initiate various treatments. Home sleep testing utilization is gaining ground because it typically costs a fourth of the cost of traditional laboratory studies.
ProAct Health Solutions provides a national program for the management of chronic diseases, such as Obstructive Sleep Apnea. ProAct’s program improves the delivery of chronic care through the use of its proprietary cloud-based solution that integrates population screening, testing, diagnostics, therapy selection treatment initiation, monitoring and compliance. ProAct provides an at-home patient management infrastructure that, until now, was available only for in-hospital acute care.
"We are excited to partner with ProAct in their effort to deliver a comprehensive solution for healthcare providers to identify and care for patients with Obstructive Sleep Apnea. Our ability to meet ProAct’s complex needs further demonstrates the sophistication of the SleepView web platform and CleveMed’s agility in this market", said Kirk Scovill, Director of National Accounts & Strategic Partnerships. "CleveMed’s SleepView product is ideal for accurately diagnosing OSA in the comfort of the patient’s home at dramatically reduced cost. When OSA is successfully identified and managed, the clinical and cost impact of many associated diseases is significantly reduced," said Scott Adams, ProAct’s COO & President.
Read the complete news release here >>
October 2nd, 2013 by Jerusha Michael
CleveMed, a leader in Home Sleep Testing equipment and cloud-based services, announced today that it was issued a patent (U.S. Patent No. 8,545,416) from the United States Patent Office for an application covering the design of an integrated sleep diagnostic and therapy technology. The patent covers the adjustment of the most common sleep apnea therapy, CPAP (Continuous Positive Airway Pressure), based on input from one or more physiological sensors placed on the patient. Like other chronic treatments, CPAP therapy will need to incorporate long-term efficacy information, beyond the currently-required 90 days, which often necessitates physiological information that cannot be measured by sensors inside the CPAP machine. This method of therapy management is particularly useful for sleep apnea patients with comorbidities, whose conditions can significantly change after CPAP initiation but have no means of conveniently monitoring or adjusting their treatments especially from the home. The affected population can be huge since the prevalence of coexisting diseases with sleep apnea is higher than 50% in many cases, suggesting that potentially millions of sleep apnea patients can benefit from such management of care.
“This is our third significant patent in this particular field covering the areas of titration, follow-up, and compliance of patients on auto-titrating PAP, Bi-Level and CPAP therapies. We believe these patents form the basis of a very strong Intellectual Property (IP) portfolio for CleveMed for the foreseeable future,” said Brian Kolkowski, CleveMed Executive VP and General Counsel. “Our IP strategy supports our vision of leading the next frontier in sleep medicine: long-term sleep therapy monitoring and management in the home, especially for patients with comorbidities,” said Hani Kayyali, CleveMed president. “Reimbursement pressures will shift chronic patient care from the hospitals to the homes, raising the need for effective and easy-to-use management tools and methods for CPAP and other OSA treatments.” Patients without comorbidities can also benefit from the technologies covered by CleveMed’s patents. Currently patients respond differently to the various CPAP machines on the market, especially auto-titrating PAP. Data from external patient sensors may provide the additional physiological information needed to prevent patient response variability.
Read complete news release here >>
July 5th, 2013 by Jerusha Michael
CleveMed announces the release of IDcheck to verify the identity of patients during home sleep studies with SleepView®. Home sleep testing with IDcheck meets the requirements of many department of transportation guidelines while providing patients with a lower cost alternative to fulfill required testing. The diagnosis and treatment of sleep apnea is vital for preventing daytime sleepiness in drivers, which is a leading factor in auto accidents.
An estimated 40 million people in the US alone are affected by a sleep disorder, many of whom are undiagnosed. About 30 million Americans have undiagnosed Sleep Apnea. Sleep Apnea is the intermittent failure to breathe while you sleep. Obstructive Sleep Apnea (OSA) is the most common type of Apnea. In this form of the disease, the airway collapses, cutting off air flow to the lungs. As Obstructive Sleep Apnea progresses, it has a cumulative effect. This means that the longer the disease goes untreated, the greater the negative side effects and associated health risks. If sleep apnea remains untreated, other health conditions may emerge or current health problems may worsen, including: high blood pressure, heart disease, stroke and diabetes.
“IDcheck is worn discreetly under the patient’s shirt, allowing the patient to fully participate in activities during the day,” said Sarah Weimer, Director of sleep products, “this is important for patient acceptance and makes the home sleep test very convenient.”
Read complete news release here >>
March 4th, 2013 by Jerusha Michael
CleveMed is excited to promote sleep disorders awareness during the National Sleep Foundation Sleep Awareness Week. According to the foundation “March 3-10 is the National Sleep Foundation’s annual week-long campaign to celebrate the health benefits of sleep. The Week begins with the release of NSF’s Sleep in America® poll on Monday, March 4, and ends with the return to Daylight Saving Time, when clocks move ahead one hour and too many Americans lose an hour of sleep!”
Did you know that over 32 million patients suspected of obstructive sleep apnea (OSA) remain undiagnosed and untreated? Patients with untreated OSA are at significantly higher risk for developing hypertension, diabetes, heart disease, obesity and sudden death.
Visit CleveMed’s social media for new resources each day this week promoting sleep disorders awareness and home sleep testing for better sleep health: